Search clinical trials for: Estrogen therapy

Total 54166 results

University of Colorado, Denver

Completed

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

Cardiovascular Disease | Cognitive Impairment | Endothelial Dysfunction | Executive Dysfunction

United States
Palleos Healthcare GmbH
Pfizer; Cankado GmbH; WSG WOMEN´S HEALTHCARE STUDY GROUP; AGO-TraFo; AGO-B; Deutsche...

Terminated

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (PRECYCLE)

Breast Neoplasm

Germany
Brock University
Dr. Peter C. Fritz, Periodontal Wellness & Implant Surgery

Terminated

Predictors of Periodontal Outcomes Post-sanative Therapy

Periodontal Diseases | Periodontal Pocket

Canada
University of Virginia

Withdrawn

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer (Breast 51)

Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
Hend Reda Sakr

Completed

Effect of Soy Phytoestrogens and Acupuncture on Bone Mineral Density in Female Athlete Triad at Adolescence Age

Osteoporosis, Osteopenia

Egypt
Pfizer

Completed

Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China

Breast Neoplasms

China
Huazhong University of Science and Technology
Wuhan University; Wuhan Union Hospital, China; The Third People's Hospital of... and other collaborators

Completed

Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori

Helicobacter Pylori Infection

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

HER2/Neu Negative | Estrogen Receptor-positive Breast Cancer | Stage IV Breast Cancer AJCC v6 and v7

United States
Trieu, Nguyen Thi, M.D.

Completed

Hormone Estradiol Replacement Therapy Additional Herbals (WH)

Menopause

Vietnam
Novartis Pharmaceuticals

Completed

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1)

Breast Cancer

United States
ETOP IBCSG Partners Foundation

Completed

Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07 (SOLE-EST)

Breast Cancer

Australia, Belgium
University of Washington

Terminated

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy (ITOMIC)

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7

United States
Universitair Ziekenhuis Brussel

Completed

SHorter Treatment of Replacement Therapy for Frozen Embryo Transfer (FET) (ShoRT)

Infertility

Belgium
Robert Bosch Gesellschaft für Medizinische Forschung...

Completed

Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients (TAMENDOX)

Breast Cancer | DCIS

Germany
Genentech, Inc.

Completed

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Non-Hodgkin's Lymphoma | Solid Cancers

United States, Spain, France, Canada
AstraZeneca

Completed

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced or

Korea, Republic of
Haukeland University Hospital
Pfizer; AstraZeneca; Helse Vest

Active, not recruiting

PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PETREMAC)

Breast Cancer

Norway
University of Washington
National Cancer Institute (NCI)

Terminated

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Recurrent Breast Carcinoma | Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
University of California, San Francisco
San Francisco AIDS Foundation; California HIV/AIDS Research Program

Completed

Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy (I-BrEATHe)

HIV Prevention | Transgender Health

United States
Aljazeera Hospital
Cairo University

Completed

Added Value of N Acetyle Cysteine to Clomiphene Citrate in PCO

PCO

Egypt
Genentech, Inc.

Terminated

A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy (HydranGea)

Breast Cancer

United States, Spain, United Kingdom, Germany, Korea, Republic of, Australia
University of Arkansas
OSI Pharmaceuticals

Terminated

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Metastatic Breast Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Head and Neck Squamous Cell Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Non-small Cell Lung Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Colorectal Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Ovarian Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Urothelial Carcinoma
Saint Petersburg State Budgetary Healthcare Institution...

Active, not recruiting

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

The Neoadjuvant Therapy

Russian Federation
University of Cagliari

Unknown

Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS)

Adenomyosis | Chronic Pelvic Pain
Centre Hospitalier Universitaire de Besancon
Pierre Fabre Medicament

Terminated

A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease (VICTORIANE)

Breast Cancer

France
Spanish Breast Cancer Research Group
Pfizer; AstraZeneca

Completed

Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors (PEARL)

Metastatic Breast Cancer

Spain, Israel, Hungary, Austria
Southwest Oncology Group
National Cancer Institute (NCI); NCIC Clinical Trials Group

Completed

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

Breast Cancer

Canada, United States
Rush University Medical Center

Withdrawn

Estrogen Therapy as Prevention in the Progression of Aneurysm (EPPA) Trial (EPPA)

Menopause | Treatment | Cerebral Aneurysm

United States
First Hospital of China Medical University
Jilin Provincial Tumor Hospital; The First Hospital of Jilin University; Second... and other collaborators

Unknown

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

Breast Cancer

China
Istituto Oncologico Veneto IRCCS
University of Padova

Completed

Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients (GIADA)

Breast Cancer

Italy
University of California, San Francisco
Novartis

Completed

Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

Breast Cancer

United States
Imperial College London

Withdrawn

Mild Cognitive Impairment in Men Following Androgen Deprivation

Prostate Cancer

United Kingdom
Yuehua Huang

Completed

A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)

Hepatocellular Carcinoma

China
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States, Canada
Translational Oncology Research International
University of California, Los Angeles; AstraZeneca; Genentech, Inc.

Terminated

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Breast Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Terminated

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Ovarian Cancer | Endometrial Cancer | Solid Tumors

United States
UNICANCER
Breast International Group

Completed

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure (ULTIMATE)

Breast Cancer | Menopause | Estrogen Receptor Positive Tumor | Hormone Antagonist

France, Sweden, Spain
Peking University First Hospital

Completed

Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China

Breast Cancer | Predictive Value of Tests | Neoadjuvant Therapy | Prognosis | HER2 | Neoplasm Staging | Estrogen Receptor | Histological Grade

China
Weill Medical College of Cornell University

Withdrawn

CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (CIMER)

Breast Cancer
Novartis Pharmaceuticals

Completed

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)

Breast Cancer

United States, China, Belgium, Canada, France, Italy, Taiwan, United Kingdom, Hungary, Australia, Spain, Germany, Singapore, Austria, Japan, Israel, Russian Federation, Korea, Republic of, Thailand, Slovakia, South Africa, Switzer... and more
Istituti Clinici Scientifici Maugeri SpA

Completed

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Female | Neoplasm Malignant | Breast

Italy
University Hospital Inselspital, Berne

Terminated

Maturation of Follicles After Transplantation of Ovarian Tissue Into the Pelvic Wall and the Ovary (Ovartrans)

Infertility | Ovarian Failure, Premature

Switzerland
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaborators

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

HER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Peru, South Africa
Kyoto Breast Cancer Research Network

Terminated

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Breast Cancer

Japan

3

Subscribe